Communiqués Addex Therapeutics Ltd Nasdaq

Actions

ADXN

US00654J2069

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:30:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
3,180 ^USD	+1,60%		+6,71%	-58,81%

08/10	L’indice SMI recule ; les actions Novartis en baisse	MT
08/10	Neurosterix, société issue de la scission d’Addex Therapeutics, fera progresser son médicament contre la schizophrénie vers des essais de phase 2	MT

Communiqués

08/10	Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia	GL
02/10	Addex Therapeutics Announces Executive Management Changes	GL
28/09	Addex Therapeutics : Half Year Report ( 436)	PU
28/09	Addex Therapeutics Reports 2026 Half-Year Results and Provides Corporate Update	GL
25/09	Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior	GL
24/09	Addex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026	GL
26/08	ADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027	GL
08/07	Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness	GL
30/06	Addex Therapeutics : Results ( 434)	PU
30/06	Addex Shareholders Approve All Resolutions at Annual General Meeting	GL
26/06	Addex Therapeutics : Quarter 1 Report ( 433)	PU
25/06	Addex Therapeutics : Quarter 1 Report (561782364078Addex Therapeutics Q1 2026 financial statements)	PU
25/06	Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
22/06	Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026	GL
08/06	Addex Convenes Annual General Meeting 2026	AQ
05/06	Addex Therapeutics : Invitation ( 432)	PU
05/06	Addex Convenes Annual General Meeting 2026	GL
30/04	Addex Therapeutics : Annual Report ( 431)	PU
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	GL
30/04	Addex Reports Full Year 2025 Financial Results and Provides Corporate Update	AQ
29/04	Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model	GL
23/04	Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026	GL
21/04	Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	GL
21/04	Addex Therapeutics : GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model	PU
03/02	Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment	GL